DTx Pharma
DTx Pharma was a San Diego-based biotechnology company developing siRNA therapies for neurological disorders, with proprietary blood-brain barrier delivery technology. Acquired by Novartis in July 2023, its programs are now part of Novartis's genetic medicine research operations.
- Company typePrivate
- Founded2017
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What DTx Pharma does
DTx Pharma was a US-based biotechnology company founded in 2017 and headquartered in San Diego, specializing in the development of RNA-based therapeutics for neurological disorders. Its core focus was small interfering RNA (siRNA) therapies targeting the genetic drivers of disease, with a particular emphasis on neuropathic pain — a market projected to reach $8.48 billion by 2030 at an 8.1% CAGR, driven by demand for non-opioid treatment alternatives. The company's core technology centered on proprietary siRNA delivery platforms, including novel mechanisms for crossing the blood-brain barrier to enable central nervous system (CNS) gene silencing, and capsid targeting platforms designed to deliver therapeutics to muscle, heart, and CNS tissues. Underlying chemistry and drug development were led by VP Charles Allerson, with VP Bryan Laffitte directing biology.
DTx Pharma operated as a clinical-stage company with no commercial products or revenue-generating operations. Its business model was structured around advancing a pipeline of siRNA candidates toward clinical milestones, supported by venture capital and non-dilutive grant funding. The company raised approximately $113.6 million in total financing across multiple rounds between 2018 and 2021, including a $100 million Series B led by RA Capital Management in March 2021 with participation from Eli Lilly, Cormorant Asset Management, Janus Henderson Investors, Logos Capital, Access Biotechnology, and others. A grant from the National Institute of Neurological Disorders and Stroke (NINDS) in September 2020 provided additional non-dilutive support. Leadership included co-founder and CEO Arthur Suckow, co-founder Adam Pavlicek, COO Denise Bevers, CMO Michael Huang, and CBO Peter Condon.
In July 2023, DTx Pharma was acquired by Novartis AG as part of the pharmaceutical company's strategy to expand its genetic medicine research capabilities in siRNA-based neurological therapeutics. Following the acquisition, DTx Pharma's operations, technology platform, and team were consolidated into Novartis's San Diego genetic medicine research center, joining earlier Novartis genetic medicine assets from the AveXis (2018) acquisition and later integrating with Kate Therapeutics (2024) under Executive Director Bryan Laffitte. The company's xRNA technology and siRNA delivery programs now sit within Novartis's broader portfolio targeting neuromuscular and neurodegenerative diseases.
DTx Pharma firmographics
Firmographics- Name
- DTx Pharma
- Legal name
- DTx Pharma
- Website
- https://dtxpharma.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Acquired
- Headcount range
- 11–50 employees
- Short description
- DTx Pharma was a San Diego-based biotechnology company developing siRNA therapies for neurological disorders, with proprietary blood-brain barrier delivery technology. Acquired by Novartis in July 2023, its programs are now part of Novartis's genetic medicine research operations.
- Ownership category
- akta.pro rank
DTx Pharma industry classification
Industry- Product category
- RNA-based Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- siRNA Therapeutics (gene silencing) (HLAAADAB)
- akta.pro secondary industry
- RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH)
Keywords
Where DTx Pharma is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
DTx Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain
DTx Pharma product offering
Product offeringCore offering
DTx Pharma develops RNA-based therapeutics, with a primary focus on siRNA (small interfering RNA) therapies designed to treat neurological disorders. The company's core technology enables siRNA molecules to cross the blood-brain barrier and target tissues in the central nervous system, muscle, and heart, addressing neuropathic pain and related neurological conditions through gene-silencing mechanisms.
Product overview
DTx Pharma was a US-based biotechnology firm that developed siRNA (small interfering RNA) therapies targeted at neurological disorders including neuropathic pain. The company was acquired by Novartis AG in July 2023 to strengthen Novartis's capabilities in developing siRNA therapies for neurological conditions. Following the acquisition, DTx Pharma's programs and expertise were integrated into Novartis's unified genetic medicine research team in San Diego, combining with existing capabilities from AveXis (2018) and Kate Therapeutics (2024) under Executive Director Bryan Laffitte. The focus areas include siRNA delivery technologies targeting muscle, heart, and CNS tissues, as well as blood-brain barrier crossing mechanisms for treating neurological conditions.
Differentiator
Problem solved
Functional benefit
Products and services
- siRNA Therapies for Neurological Disorders RNA-based therapeutic candidates that use small interfering RNA to silence disease-driving genes in the central nervous system, enabled by DTx's proprietary blood-brain barrier-crossing delivery technology. Targeted at patients with neuropathic pain and related neurological disorders; the development programs and platform were acquired by Novartis AG in July 2023 to be advanced through late-stage development and commercialization.
Companies that use DTx Pharma
Customer profileSegments1 record
Ideal customer profiles1 record
DTx Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
DTx Pharma partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights4 records
DTx Pharma competitors and assessment
Company assessmentDirect peers
- Alnylam Pharmaceuticals: The leading clinical-stage and commercial siRNA therapeutics company, with multiple approved products (Onpattro, Givlaari, Oxlumo, Amvuttra) and a deep CNS/cardiovascular pipeline. Directly comparable to DTx Pharma on siRNA modality, though at a far more advanced clinical and commercial stage.
- Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) therapeutics — the closest mechanistic peer to siRNA in the RNA-based drug modality. Has multiple approved products and active programs in neurological disorders, including spinal muscular atrophy (Spinraza), making it a strong direct competitor in CNS-targeted RNA therapeutics.
- Arrowhead Pharmaceuticals: Clinical-stage RNAi therapeutics company with proprietary TRiM™ delivery platform targeting multiple tissues including the CNS. Competes directly with DTx Pharma in siRNA delivery innovation for neurological and rare disease indications.
- Silence Therapeutics: Clinical-stage siRNA therapeutics company developing GalNAc-conjugated siRNAs for cardiovascular and hematological diseases. Directly comparable on siRNA platform technology, though with less CNS focus than DTx Pharma.
- Wave Life Sciences: Clinical-stage RNA therapeutics company developing stereopure oligonucleotide therapeutics, with active programs in Huntington's disease and other neurological disorders. Comparable to DTx in neurological RNA therapeutic focus.
Emerging players
- Atalanta Therapeutics: Emerging CNS-focused RNAi therapeutics company developing siRNA therapies for neurodegenerative diseases. Directly comparable to DTx's CNS siRNA focus but at an earlier stage with a narrower therapeutic scope.
- Design Therapeutics: Clinical-stage biotechnology company developing novel small molecules for serious genetic disorders including neurological indications like Friedreich's ataxia. Adjacent peer in the neurological genetic medicine space, though focused on small molecules rather than siRNA.
Broad incumbents
- Novartis AG: Parent company of DTx Pharma and a major global pharmaceutical company with significant neurological and rare disease franchises (including gene therapy via AveXis/Zolgensma). Represents both the validation of DTx's platform and the broader competitive landscape for neurological therapeutics.
- Biogen: Major pharmaceutical company with deep neurological disease franchise (multiple sclerosis, spinal muscular atrophy, Alzheimer's). Represents broad incumbent competition for neurological therapeutics development and commercialization.
Others
- Eli Lilly and Company: Investor in DTx Pharma's $100M Series B (2021) and a major pharmaceutical company with active neurological disease programs including Alzheimer's disease. Connected to DTx both as a prior capital provider and as a broader industry incumbent in neurology.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
DTx Pharma social profiles
Digital presenceDTx Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
DTx Pharma leadership team
Management profileNumber of profiles
Profiles8 records
DTx Pharma funding detail
Funding detailFunding overview
Funding rounds5 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DTx Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DTx Pharma
What does DTx Pharma do?
DTx Pharma develops RNA-based therapeutics, with a primary focus on siRNA (small interfering RNA) therapies designed to treat neurological disorders. The company's core technology enables siRNA molecules to cross the blood-brain barrier and target tissues in the central nervous system, muscle, and heart, addressing neuropathic pain and related neurological conditions through gene-silencing mechanisms.
Is DTx Pharma a public or private company?
DTx Pharma is a private company. It is classified as corporate owned and is currently acquired.
When was DTx Pharma founded?
DTx Pharma was founded in 2017. It employs 11 to 50 people.
Where is DTx Pharma based?
DTx Pharma is headquartered in San Diego, United States, in the North America region.
Who are DTx Pharma's main competitors?
Direct peers on record are Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics and Wave Life Sciences. Emerging players are Atalanta Therapeutics and Design Therapeutics. Broad incumbents are Novartis AG and Biogen. Eli Lilly and Company is listed as an others.
Does DTx Pharma have an API?
No public API is recorded for DTx Pharma.
What industry is DTx Pharma in?
DTx Pharma's product category is RNA-based Therapeutics. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 325414 and its SIC code is 2834.